Advice for Testing Practices in Non-Small Cell Lung Cancer
Anne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses key takeaways on a presentation around managing non–small cell lung cancer cases in patients with contralateral lung nodules and dominant tumors.
Anne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses key takeaways on a presentation around managing non–small cell lung cancer (NSCLC) cases in patients with contralateral lung nodules and dominant tumors.
The most important step when beginning to care for a patients with these characteristics is to perform a liquid biopsy and a tissue biopsy when there is tissue available for both the nodules and dominant disease. The results of testing will provide information that will aid treatment choices. Testing should also be performed when patients progress, says Chiang. A second round of testing will be most relevant n patients who have a second tumor or a mixed tumor because the progression can be in one of the tumor’s clones and this would require a change in therapy.
Aside from what is already known about NSCLC's heterogenous nature, Chiang stresses the importance of staying abreast of clinical trial research as new treatment options may become available for patients in certain subgroup populations.
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC
April 7th 2024An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
April 5th 2024During a Case-Based Roundtable® event, Christine Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non-small cell lung cancer in the first article of a 2-part series.
Read More
